NU-CEFUROXIME TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

CEFUROXIME (CEFUROXIME AXETIL)

Mevcut itibaren:

NU-PHARM INC

ATC kodu:

J01DC02

INN (International Adı):

CEFUROXIME

Doz:

500MG

Farmasötik formu:

TABLET

Kompozisyon:

CEFUROXIME (CEFUROXIME AXETIL) 500MG

Uygulama yolu:

ORAL

Paketteki üniteler:

60/100/500

Reçete türü:

Prescription

Terapötik alanı:

SECOND GENERATION CEPHALOSPORINS

Ürün özeti:

Active ingredient group (AIG) number: 0122448002; AHFS:

Yetkilendirme durumu:

CANCELLED (UNRETURNED ANNUAL)

Yetkilendirme tarihi:

2018-03-28

Ürün özellikleri

Page 1 of 26
PRODUCT MONOGRAPH
PR
NU-CEFUROXIME
CEFUROXIME AXETIL TABLETS
250 MG AND 500 MG CEFUROXIME/TABLET
NU-PHARM STANDARD
ANTIBIOTIC
NU-PHARM INC.
DATE OF PREPARATION:
50 MURAL ST., UNITS 1 & 2
OCTOBER 20, 2009
RICHMOND HILL, ONTARIO
L4B 1E4
CONTROL#: 133377
Page 2 of 26
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................................3
SUMMARY PRODUCT
INFORMATION.................................................................................3
INDICATIONS AND CLINICAL
USE.......................................................................................3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND
PRECAUTIONS.........................................................................................4
ADVERSE REACTIONS
.........................................................................................................5
DRUG
INTERACTIONS..........................................................................................................6
DOSAGE AND
ADMINISTRATION.........................................................................................6
OVERDOSAGE.......................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................7
STORAGE AND STABILITY
...................................................................................................7
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................7
PART II: SCIENTIFIC
INFORMATION.......................................................................................9
PHARMACEUTICAL
INFORMATION.....................................................................................9
CLINICAL
TRIALS.......................................................................................................